Suffering from prostate cancer or benign prostatic hyperplasia (BPH) is not the end of a relationship. Technology and ...
AngioDynamics (Nasdaq:ANGO) announced today that it received FDA investigational device exemption (IDE) to initiate the ...
AngioDynamics has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption ...
Zacks Investment Research on MSN
ANGO gains FDA IDE approval for NanoKnife BPH feasibility study
AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will ...
8d
FineTreatment Highlights Rising Interest in Non-Invasive Therapies for Benign Prostatic Hyperplasia
OXFORD, UK / ACCESS Newswire / June 15, 2026 /Fine Treatment has highlighted increasing interest in non-invasive therapeutic ...
A postmarketing study showed that the Optilume BPH system improved the flow of urine while leaving sexual function unchanged in men with benign prostatic hyperplasia (BPH), researchers reported at the ...
Cooley Dickinson Hospital is celebrating four years of providing Aquablation therapy, an advanced treatment for benign ...
14d
JW Pharmaceutical and JW Shinyak Hold Symposium on Benign Prostatic Hyperplasia Treatment "Truepass"
JW Pharmaceutical and JW Shinyak announced on the 10th that they held the "J STAR Symposium" at the Grand Walkerhill Seoul ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results